Ranolazine decreases angina
نویسندگان
چکیده
منابع مشابه
Update on evidence for treatment with ranolazine in stable angina.
Chronic angina represents a major burden for public health systems because of its poor prognosis and its high treatment costs. Ranolazine is an emerging drug recently approved for the treatment of this disease. The main molecular mechanism underlying ranolazine-mediated beneficial effects has been identified as inhibition of the late Na+ current during the action potential, which potentially im...
متن کاملDRUG EVALUATION Ranolazine extended-release for chronic angina
Coronary heart disease affects over 15 million people in the USA, and approximately 9 million have angina pectoris [101]. However, this likely represents only the ‘tip of the iceberg’ of symptomatic chronic coronary disease syndromes (CCS), considering diffi culties with recognition of chest symptoms and access to medical care capable of making an appropriate diagnosis. In Americans aged 40–74 ...
متن کاملUtility of ranolazine in chronic stable angina patients
Chronic stable angina is a debilitating illness affecting at least 6.6 million US residents. Despite being optimally treated by pharmacotherapy and revascularization up to 26% of patients still experience angina. Diabetes mellitus is a common co-morbid condition in angina patients. Several new investigational medications are being tested for chronic angina. Advances in understanding of myocardi...
متن کاملEmerging clinical role of ranolazine in the management of angina
Chronic stable angina is an exceedingly prevalent condition with tremendous clinical, social, and financial implications. Traditional medical therapy for angina consists of beta-blockers, calcium channel blockers, and nitrates. These agents decrease myocardial oxygen demand and ischemia by reducing heart rate, lowering blood pressure, and/or optimizing ventricular loading characteristics. Uniqu...
متن کاملRanolazine: a novel therapeutic option in chronic stable angina.
hronic stable angina (CSA) represents the largest cardiovascular disorder in the United States and is the initial clinical presentation of ischemic heart disease in 50% of patients. CSA is the result of the progression of coronary atherosclerosis and becomes symptomatic once the luminal diameter of the vessel is occluded by >50%. Current medical therapy is targeted at reducing the frequency of ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Cardiology
سال: 2013
ISSN: 1759-5002,1759-5010
DOI: 10.1038/nrcardio.2013.42